CLINICAL UTILITY OF A BAYESIAN DOSING PROGRAM FOR PHENYTOIN

被引：27

作者：

PRIVITERA, MD

HOMAN, RW

LUDDEN, TM

PECK, CC

VASKO, MR

机构：

[1] UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,SAN ANTONIO,TX 78284

[2] UNIFORMED SERV UNIV HLTH SCI,DEPT PHARMACOL & MED,BETHESDA,MD 20814

[3] VET ADM MED CTR,DEPT NEUROL,DALLAS,TX 75216

[4] VET ADM MED CTR,DEPT PHARMACOL,DALLAS,TX 75216

来源：

THERAPEUTIC DRUG MONITORING | 1989年 / 11卷 / 03期

关键词：

D O I：

10.1097/00007691-198905000-00011

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

引用

页码：285 / 294

页数：10

共 38 条

[1]

ARNOLD K, 1970, CLIN PHARMACOL THER, V11, P121

[2] INDIVIDUALIZATION OF ANTICONVULSANT THERAPY [J].

ATKINSON, AJ .

MEDICAL CLINICS OF NORTH AMERICA, 1974, 58 (05) :1037-1049

[3] COMPUTATION OF THE EXPLICIT SOLUTION TO THE MICHAELIS-MENTEN EQUATION [J].

BEAL, SL .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (06) :641-657

[4] EFFECT OF DOSAGE INCREMENTS ON BLOOD PHENYTOIN CONCENTRATIONS [J].

BOCHNER, F ;

HOOPER, WD ;

TYRER, JH ;

EADIE, MJ .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1972, 35 (06) :873-876

[5]

BUCHTHAL F, 1972, ANTIEPILEPTIC DRUGS, P193

[6] ELIMINATION OF PHENYTOIN IN MAN [J].

EADIE, MJ ;

TYRER, JH ;

BOCHNER, F ;

HOOPER, WD .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 1976, 3 (03) :217-224

[7]

GERBER N, 1972, RES COMMUN CHEM PATH, V3, P455

[8]

GODLEY PJ, 1987, CLIN PHARMACY, V6, P634

[9] STEADY-STATE PHARMACOKINETICS OF PHENYTOIN FROM ROUTINELY COLLECTED PATIENT DATA [J].

GRASELA, TH ;

SHEINER, LB ;

RAMBECK, B ;

BOENIGK, HE ;

DUNLOP, A ;

MULLEN, PW ;

WADSWORTH, J ;

RICHENS, A ;

ISHIZAKI, T ;

CHIBA, K ;

MIURA, H ;

MINAGAWA, K ;

BLAIN, PG ;

MUCKLOW, JC ;

BACON, CT ;

RAWLINS, M .

CLINICAL PHARMACOKINETICS, 1983, 8 (04) :355-364

[10] PHENYTOIN CLEARANCES IN A COMPLIANT POPULATION - DESCRIPTION AND APPLICATION [J].

GRAVES, NM ;

LEPPIK, IE ;

TERMOND, E ;

TAYLOR, JW .

THERAPEUTIC DRUG MONITORING, 1986, 8 (04) :427-433

← 1 2 3 4 →